Beta Bionics (NASDAQ:BBNX) Coverage Initiated by Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH started coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report published on Thursday morning, MarketBeat.com reports. The firm issued a neutral rating and a $20.00 target price on the stock.

Separately, Robert W. Baird began coverage on shares of Beta Bionics in a research note on Thursday. They set a “neutral” rating and a $20.00 price target for the company.

Beta Bionics Price Performance

Shares of BBNX opened at $20.87 on Thursday. Beta Bionics has a 1-year low of $20.84 and a 1-year high of $24.50.

Insider Activity at Beta Bionics

In related news, insider Mike Mensinger bought 33,350 shares of the stock in a transaction on Friday, January 31st. The stock was bought at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the acquisition, the insider now directly owns 59,019 shares in the company, valued at approximately $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the completion of the acquisition, the insider now directly owns 3,901,599 shares in the company, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their position. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.